- Trial phase
- Approved (US)
- Time to market
- Already approved and marketed in the U.S. (first FDA approval Feb 22, 2023); sold commercially
- Why 3/10
- ALTUVIIIO was already FDA-approved (February 22-23, 2023) and is commercializing with no pending regulatory decision or pivotal readout scheduled in the next ~12 months, SecBot's local data shows no upcoming FDA catalyst for SNY, and it is a small slice of a roughly $109B company, so no hard dated binary exists to drive a large share-price move.
For SNY holders, ALTUVIIIO is a genuine growth product but not a stock-moving event: the approval binary passed in Feb 2023, and Sanofi's share-price catalysts live elsewhere (e.g., Dupixent momentum and a venglustat FDA decision reportedly targeted Nov 25, 2026). Watch quarterly Sanofi disclosures for ALTUVIIIO sales growth and the pending presentation of a completed Phase 3 joint-health study (NCT05817812, results not yet posted) as the main drug-specific updates.
Price Chart
Executive Summary
ALTUVIIIO (efanesoctocog alfa, formerly BIVV001) is Sanofi's first-in-class once-weekly factor VIII replacement therapy for hemophilia A, FDA-approved Feb 22-23, 2023 for adults and children, covering routine prophylaxis, on-demand bleeding control, and surgery. It delivers ~3-4x longer half-life than standard/extended half-life factor VIII products and is commercializing with Sobi as partner. The drug is a real growth contributor for Sanofi (a ~$109B company that grew H1 2026 net sales +11.1% reported / +15.7% CER), but the approval catalyst has passed, competition is stiff, and no ALTUVIIIO-specific binary is scheduled, hence a neutral investor read at the SNY level.
How It Works
Hemophilia A patients lack working clotting factor VIII, so they bleed easily. ALTUVIIIO is an engineered version of factor VIII (fused to pieces of the von Willebrand factor protein plus 'Fc' and 'XTEN' segments) that keeps working on its own in the bloodstream instead of depending on the body's natural VWF. That gives it a roughly 3-4x longer half-life than standard factor VIII, so patients need only one injection a week instead of several, and it keeps clotting-factor levels high enough to nearly eliminate bleeds.
Trial Status
Approved in the US for hemophilia A (adults and children) in Feb 2023 for prophylaxis, on-demand treatment, and surgery; a Phase 3 study of once-weekly efanesoctocog alfa on physical activity and joint health in severe hemophilia A (NCT05817812, Sobi-sponsored) completed June 2, 2026 with results not yet posted.
The Two-Sided Case
Upcoming Catalysts
- Publication/presentation of results from the completed Phase 3 physical-activity and joint-health study (NCT05817812), timing not yet announced
- Quarterly Sanofi earnings disclosures of ALTUVIIIO sales (H2 2026 / full-year report), growth updates, not binary events
- No FDA PDUFA, advisory committee, or pivotal readout for ALTUVIIIO scheduled in SecBot's local 30-90 day catalyst window
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report